Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Francisco, California 94103


Purpose:

The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective in lowering the amount of HIV in the blood of patients who have been treated with more than 1 protease inhibitor (PI).


Study summary:

All patients take ABT-378/ritonavir and efavirenz; there are no placebos in this study. Patients take study medications for 48 weeks, during which time there will be 15 study visits. There is a possibility of a study extension after 48 weeks.


Criteria:

Inclusion Criteria Patients may be eligible for this study if they: - Are HIV-positive. - Have a viral load (level of HIV in the blood) of at least 1,000 copies/ml. - Have been receiving stable (no changes) anti-HIV treatment that includes at least 1 PI for at least 8 weeks prior to study entry. - Have received more than 1 PI for at least 12 weeks each at some time in the past. Exclusion Criteria Patients will not be eligible for this study if they: - Have had any active opportunistic (AIDS-related) infections within the past 30 days. - Have ever received nonnucleoside reverse transcriptase inhibitors (NNRTIs), such as delavirdine, nevirapine, or efavirenz. - Have received certain medications. - Are pregnant or breast-feeding. - Abuse alcohol or drugs.


NCT ID:

NCT00004582


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

San Francisco, California 94103
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.